Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AN9025 in Advanced or Metastatic Solid Tumors Harboring RAS Mutations
NCT07252479Phase 1Recruiting
- Sponsor
- Adlai Nortye
- Start
- Jan 2026
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of AN9025 in solid tumor, sponsored by Adlai Nortye. Primary endpoint: Dose Limiting Toxicities at 21 days. Started Jan 2026; status: recruiting.
02
Drugs
AN9025
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07252479.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07252479.